Hypogammaglobulinemia in Multiple Sclerosis Patients Receiving Disease-Modifying Immunomodulatory Agents

被引：0
|
作者：
Tsao, Lulu [1 ]
Otani, Iris M. [2 ]
Bove, Riley [3 ]
机构：
[1] UCSF, Dept Med, San Francisco, CA USA
[2] UCSF, Dept Internal Med, Div Allergy & Immunol, San Francisco, CA USA
[3] UCSF, Dept Neurol, San Francisco, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2019年 / 143卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
49
引用
收藏
页码：AB17 / AB17
页数：1
相关论文
共 50 条
  • [21] Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
    Etemadifar, Masoud
    Sami, Ramin
    Salari, Mehri
    Sedaghat, Nahad
    Sigari, Amirhossein Akhavan
    Aghababaei, Ali
    Najafi, Mohammadreza
    Tehrani, Donya Sheibani
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [22] Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study
    Minden, S.
    Hoaglin, D.
    Jureidini, S.
    Hadden, L.
    Frankel, D.
    Komatsuzaki, Y.
    Outley, J.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (05) : 640 - 655
  • [23] Disease-modifying therapies for multiple sclerosis
    John R. Corboy
    Douglas S. Goodin
    Elliot M. Frohman
    Current Treatment Options in Neurology, 2003, 5 (1) : 35 - 54
  • [24] Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis
    Lafata, Jennifer Elston
    Cerghet, Mirela
    Dobie, Elizabeth
    Schultz, Lonni
    Tunceli, Kaan
    Reuther, Jacqueline
    Elias, Stanton
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2008, 48 (06) : 752 - 757
  • [25] Adherence to Disease-Modifying Agents among Patients with Multiple Sclerosis: 5 Year Prospective Study
    Cerghet, Mirela
    Elias, Stanton
    Dobie, Liz
    Salloum, Ramzi
    Elston-Lafata, Jennifer
    Schultz, Lonni
    NEUROLOGY, 2011, 76 (09) : A72 - A73
  • [26] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [27] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [28] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
  • [29] Prescribing disease-modifying treatments for older patients with multiple sclerosis
    Lopez Ruiz, Rocio
    Eichau Madueno, Sara
    Cortes Zujar, Beatriz
    Canaveral, Marta
    Arzalluz, Joaquin
    Ben Yelun Insenser, Miriam
    Dotor, Julio
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1086 - 1086
  • [30] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    Journal of Neurology, 2017, 264 : 2325 - 2329
12345